Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA)

Historical Holders from Q1 2016 to Q3 2025

Symbol
NTLA on Nasdaq
CUSIP
45826J105
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
108M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
104M
Holdings value
$1.8B
% of all portfolios
0.002%
Grand Portfolio weight change
+0%
Number of holders
274
Number of buys
142
Number of sells
-114
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ARK Investment Management LLC 11.1% $206M 11.9M ARK Investment Management LLC Sep 30, 2025
VANGUARD GROUP INC 10% $75.5M 10.2M The Vanguard Group Dec 31, 2024
BlackRock, Inc. 8.2% $62.6M 8.45M BlackRock, Inc. Mar 31, 2025
Contrarius Investment Management Ltd 5.5% $102M 5.89M Contrarius Investment Management Ltd Sep 30, 2025
GOLDMAN SACHS GROUP INC 5.1% $95M 5.5M THE GOLDMAN SACHS GROUP, INC. Sep 30, 2025
STATE STREET CORP 4.4% $33.4M 4.51M STATE STREET CORPORATION Mar 31, 2025

Institutional Holders of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 104M $1.8B +$104M $17.27 274
2025 Q2 99.5M $934M -$6.85M $9.38 276
2025 Q1 101M $720M +$1.66M $7.11 288
2024 Q4 99.2M $1.16B -$48.8M $11.66 287
2024 Q3 93.1M $1.91B +$51.2M $20.55 277
2024 Q2 90.1M $2.02B -$18.7M $22.38 288
2024 Q1 90.4M $2.49B +$142M $27.51 279
2023 Q4 287K $8.77M +$383K $30.49 5
2023 Q3 78.9M $2.5B +$57.8M $31.62 274
2023 Q2 77.1M $3.14B -$39.8M $40.78 280
2023 Q1 78.3M $2.91B +$28.2M $37.27 280
2022 Q4 77.5M $2.71B +$329M $34.89 288
2022 Q3 67.9M $3.8B -$10.1M $55.96 301
2022 Q2 67.5M $3.44B +$102M $51.76 279
2022 Q1 64.7M $4.68B -$33.8M $72.67 335
2021 Q4 63.9M $7.56B +$200M $118.24 356
2021 Q3 61.8M $8.29B +$33.8M $134.15 355
2021 Q2 61.9M $10B +$30M $161.91 330
2021 Q1 62.8M $5.04B +$267M $80.25 253
2020 Q4 61.4M $3.34B +$177M $54.40 232
2020 Q3 56.4M $1.12B +$49.2M $19.88 158
2020 Q2 53.9M $1.13B +$161M $21.02 158
2020 Q1 46.4M $568M +$9.03M $12.23 133
2019 Q4 45.6M $669M +$24.4M $14.67 136
2019 Q3 44.1M $589M +$69.2M $13.35 130
2019 Q2 38.7M $634M +$80.4M $16.37 140
2019 Q1 33.5M $570M +$44.7M $17.08 141
2018 Q4 31.5M $430M +$12.3M $13.65 134
2018 Q3 29.1M $833M +$9.98M $28.62 149
2018 Q2 28.8M $787M +$69.1M $27.36 149
2018 Q1 26.3M $554M +$48.1M $21.09 125
2017 Q4 24.2M $464M +$126M $19.22 104
2017 Q3 17.7M $439M +$20.6M $24.85 83
2017 Q2 16.8M $269M +$2.72M $16.00 80
2017 Q1 16.5M $233M -$10.2M $14.09 73
2016 Q4 18.1M $238M -$5.66M $13.11 64
2016 Q3 14.3M $243M +$998K $17.02 64
2016 Q2 14.1M $300M +$298M $21.35 61
2016 Q1 215 $4K $0 $18.60 1